Skip to main content
. 2019 Mar 4;129(4):1407–1418. doi: 10.1172/JCI122287

Figure 3. Oncolytic immunotherapy.

Figure 3

OVs engineered to activate immune system release interleukins or chemokines after tumor cell infection, activating the immune response against the tumor. Coadministered checkpoint inhibitors prevent the inhibition of immune response, ensuring that immune cells are constantly activated against the tumor cells. APC, antigen-presenting cell.